Reduced expression of STAT3 in OC cells in vitro and in vivo via anti-miR551b-3p leads to reduction in growth of ovarian tumor in vivo, thereby implying that it could serve as promising therapeutic target in future for ovarian cancer (Chaluvally-Raghavan et al., 2016). This evidence concerns the gene STAT3 and ovarian cancer.